Transcriptomics

Dataset Information

0

Stromal HIF2 Regulated Immune Suppression in the Pancreatic Cancer Microenvironment


ABSTRACT: We used a dual recombinase mouse model to delete Hif2a in α-smooth muscle actin (αSMA)-expressing cancer-associated fibroblasts (CAFs) arising within spontaneous pancreatic tumors. The effects of CAF-Hif2a expression on tumor progression and composition of the tumor microenvironment were evaluated by Kaplan-Meier analysis, quantitative real-time polymerase chain reaction, histology, immunostaining, and by both bulk and single-cell RNA sequencing. CAF-macrophage crosstalk was modeled ex vivo using conditioned media from CAFs after treatment with hypoxia and PT2399, a HIF2 inhibitor currently in clinical trials. Syngeneic flank and orthotopic PDAC models were used to assess whether HIF2 inhibition improves response to immune checkpoint blockade. Results. CAF-specific deletion of HIF2, but not HIF1, suppressed PDAC tumor progression and growth, and improved survival of mice by 50% (n = 21-23 mice/group, Log-rank P = 0.0009). Deletion of CAF-HIF2 modestly reduced tumor fibrosis and significantly decreased the intratumoral recruitment of immunosuppressive M2 macrophages and regulatory T cells. Treatment with the clinical HIF2 inhibitor PT2399 significantly reduced in vitro macrophage chemotaxis and M2 polarization, and improved tumor responses to immunotherapy in both syngeneic PDAC mouse models. Conclusions. Together, these data suggest that stromal HIF2 is an essential component of PDAC pathobiology and is a druggable therapeutic target that could relieve tumor microenvironment immunosuppression and enhance immune responses in this disease.

ORGANISM(S): Mus musculus

PROVIDER: GSE193416 | GEO | 2022/07/20

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-12-25 | GSE192474 | GEO
| phs001840 | dbGaP
2023-02-18 | GSE221761 | GEO
2024-10-06 | E-MTAB-14494 | biostudies-arrayexpress
2024-06-21 | GSE255978 | GEO
2024-03-15 | GSE254384 | GEO
2021-09-16 | GSE183779 | GEO
2020-08-19 | PXD018899 | Pride
2024-06-24 | PXD053144 | Pride
2022-08-23 | GSE197908 | GEO